Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to compare the efficacy on pupillary dilation between the single dose versus the three doses of 1% tropicamide with 10% phenylephrine for complete ocular examination.
Condition | Intervention | Phase |
---|---|---|
Eye Diseases |
Drug: 1% tropicamide and 10% phenylephrine |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
Official Title: | Single Dose of 1% Tropicamide and 10% Phenylephrine for Pupillary Dilation |
- horizontal pupil diameter [ Time Frame: 30 min ] [ Designated as safety issue: No ]
- systolic blood pressure [ Time Frame: 30 min ] [ Designated as safety issue: Yes ]
- diastolic blood pressure [ Time Frame: 30 min ] [ Designated as safety issue: Yes ]
- heart rate [ Time Frame: 30 min ] [ Designated as safety issue: Yes ]
- adverse drug reaction [ Time Frame: 30 min ] [ Designated as safety issue: Yes ]
Enrollment: | 80 |
Study Start Date: | December 2004 |
Study Completion Date: | June 2005 |
Arms | Assigned Interventions |
---|---|
Active Comparator: A
single dose vs three doses of 1%tropicamide and 10%phenylephrine
|
Drug: 1% tropicamide and 10% phenylephrine
single dose vs three doses of 1%tropicamide and 10%phenylephrine
|
Detailed Description:
To the best of the authors' knowledge, there have been no clinical trials using an appropriate regimen for pupillary dilation up until now. Therefore, the authors were interested to find out the most appropriate regimen for complete ocular examination, based on the finding that a pupil diameter of 6 mm or greater is adequate for indirect ophthalmoscopy. The authors hypothesize that a single dose of 1% tropicamide and 10% phenylephrine is adequate to complete the job and are conducting this prospective randomized clinical controlled trial to prove the hypothesis.
Ages Eligible for Study: | 20 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- aged between 20 and 80 years old
- dark iris
- require binocular indirect ophthalmoscopy for complete ocular examination
- signed written consent forms
Exclusion Criteria:
- history of ocular trauma
- history of intraocular surgery
- history of laser treatment
- previous eye drop instillation that may affect pupillary dilation
- ocular diseases that may affect pupil size such as Horner's syndrome, Adies' pupil, glaucoma and uveitis
- history of diabetes mellitus, severe hypertension and cardiovascular diseases
Publications:
Responsible Party: | Yosanan Yospaiboon, Professor, Khon Kaen University |
ClinicalTrials.gov Identifier: | NCT00120432 History of Changes |
Other Study ID Numbers: | HE461104 |
Study First Received: | July 11, 2005 |
Last Updated: | March 7, 2012 |
Health Authority: | Thailand: Khon Kaen University Ethics Committee for Human Research |
Keywords provided by Khon Kaen University:
single dose mydriatic drug pupillary dilation |
Additional relevant MeSH terms:
Dilatation, Pathologic Eye Diseases Mydriasis Pathological Conditions, Anatomical Pupil Disorders Phenylephrine Tropicamide Oxymetazoline Adrenergic alpha-1 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
Physiological Effects of Drugs Cardiotonic Agents Cardiovascular Agents Therapeutic Uses Mydriatics Autonomic Agents Peripheral Nervous System Agents Sympathomimetics Vasoconstrictor Agents Nasal Decongestants Respiratory System Agents Protective Agents Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents |
ClinicalTrials.gov processed this record on October 16, 2012